Dexcom (DXCM) Revenue (2010 - 2026)

Dexcom (DXCM) has 17 years of Revenue data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Revenue rose 15.05% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 16.15% YoY) and the FY2025 annual result came in at $4.7 billion, up 15.6% from the prior year.
• Revenue fell to $1.2 billion in Q1 2026 per DXCM's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Revenue topped out at $1.3 billion in Q4 2025 and bottomed at $628.8 million in Q1 2022.
• The 5-year median for Revenue is $994.2 million (2024), against an average of $965.8 million.
• The widest annual swing landed in 2023, when Revenue rose 26.9%; it then climbed 1.97% in 2024.
• Tracing DXCM's Revenue over 5 years: stood at $815.2 million in 2022, then climbed by 26.9% to $1.0 billion in 2023, then gained by 7.64% to $1.1 billion in 2024, then grew by 13.12% to $1.3 billion in 2025, then decreased by 5.37% to $1.2 billion in 2026.
• Per Business Quant, the three latest DXCM Revenue figures stand at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025).

Peer Comparison